

## Summary of 1st Quarter Financial Results for year ended March 31, 2014 (Japan GAAP) (Consolidated)

July 31, 2013

Company name: Mitsubishi Tanabe Pharma Corporation  
 Stock exchange listings: Tokyo  
 Securities code number: 4508  
 URL: <http://www.mt-pharma.co.jp/>  
 Representative: Name: Michihiro Tsuchiya  
 Title: President and Representative Director  
 For further information, please contact: Name: Yoshihisa Sasou  
 Title: General Manager, Corporate Communications Department  
 Telephone: (06) 6205-5211

Planned date of filing of quarterly securities report: August 2, 2013  
 Planned date of start of dividend payments: —  
 Provision of supplementary explanatory materials for quarterly results: Yes  
 Quarterly results presentation: Yes (for institutional investors and investment analysts)

Notes: Amounts less than ¥ 1 million have been rounded.  
 Percentage changes in the list show change in comparison with the previous 1st quarter.

### 1. Results for 1st Quarter (April 1, 2013 to June 30, 2013)

#### (1) Consolidated Business Results

	Net sales		Operating income		Ordinary income	
	Yen million	% change	Yen million	% change	Yen million	% change
1st Quarter of Fiscal 2013	103,922	(0.4)	16,240	(13.8)	17,061	(13.1)
1st Quarter of Fiscal 2012	104,388	2.1	18,834	(17.2)	19,639	(14.6)

	Net income		Net income per share	Net income per share (diluted)
	Yen million	% change	Yen	Yen
1st Quarter of Fiscal 2013	10,410	(3.9)	18.56	—
1st Quarter of Fiscal 2012	10,828	(5.2)	19.30	—

(Note) Comprehensive Income ¥11,451 million, (5.4)% (¥12,108 million, 7.0% in 1st Quarter of fiscal 2012)

#### (2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Yen million	Yen million	%
As of June 30, 2013	853,686	753,122	87.6
As of March 31, 2013	866,774	752,922	86.3

(Note) Shareholders' equity ¥747,896 million (¥747,929 million in fiscal 2012)

### 2. Dividends

(Record date)	Dividends per share				
	1st Quarter	2nd Quarter	3rd Quarter	Year-end	For the year
	Yen	Yen	Yen	Yen	Yen
Fiscal 2012	—	20.00	—	20.00	40.00
Fiscal 2013	—	—	—	—	—
Fiscal 2013(projected)	—	20.00	—	20.00	40.00

(Note) Revision to recently announced dividend forecast: No

### 3. Forecasts for Fiscal 2013 (April 1, 2013 to March 31, 2014)

	Net sales		Operating income		Ordinary income	
	Yen million	% change	Yen million	% change	Yen million	% change
1st half	200,000	(1.9)	30,000	(7.0)	31,000	(6.4)
Full year	417,000	(0.5)	70,000	1.5	71,500	3.0

	Net income		Net income per share
	Yen million	% change	Yen
1st half	19,000	(2.5)	33.87
Full year	44,000	5.0	78.43

(Note) Revision to recently announced consolidated results forecast: No

## ※ Notes

- (1) Significant change involving subsidiaries during the period: No  
(Change in designated subsidiaries accompanying changes in the scope of consolidation)
- (2) Application of special accounting methods in the preparation of quarterly financial statements: No
- (3) Changes in accounting policies, changes in accounting estimates, and restatements
1. Change accompanying revision of accounting standards: No
  2. Other changes: No
  3. Change in accounting estimates: No
  4. Restatements: No

(4) Number of shares issued (common stock)

1. Number of shares issued at the end of the period (including treasury stock)

1st Quarter of fiscal 2013	561,417,916 shares	Fiscal 2012	561,417,916 shares
----------------------------	--------------------	-------------	--------------------

2. Number of shares of treasury stock at the end of the period

1st Quarter of fiscal 2013	425,327 shares	Fiscal 2012	424,977 shares
----------------------------	----------------	-------------	----------------

3. Average number of shares of during the period (cumulative third quarter)

1st Quarter of fiscal 2013	560,992,796 shares	1st Quarter of fiscal 2012	560,994,357 shares
----------------------------	--------------------	----------------------------	--------------------

\*Note regarding implementation of quarterly review procedures

At the time when this summary of 1st quarter financial results was released, the review procedures were in progress for the quarterly financial statements in accordance with the Financial Instruments and Exchange Act.

\*Explanation regarding the appropriate use of results forecasts and other matters of special note

(Note about forward-looking information)

In these materials, forecasts of results and other statements about the future are forward-looking statements based on a number of assumptions and beliefs in light of the information available to management as of the date of release of the materials and are subject to risks and uncertainties. Accordingly, the Company cannot make promises to achieve such forecasts. Actual financial results may differ materially from these forecasts depending on a number of important factors.

For matters related to results forecasts, please see page 4.

(Methods of obtaining the supplementary materials and the content of the results presentation)

- Supplementary materials are included from page 12 of this document in section "3. Supplementary information."
- The Company plans to hold a results presentation (conference call) for institutional investors and securities analysts on July 31, 2013 (Wednesday).

The Company plans to make available on its website the content of the presentation (sound) and the presentation materials immediately after the presentation is held.

Contents of supplement

- 1. Qualitative Information for 1<sup>st</sup> Quarter of FY2013 ..... 1
  - (1) Explanation about results of operations ..... 1
  - (2) Explanation about financial position ..... 3
  - (3) Explanation about future prediction information of consolidated results forecasts ..... 4
- 2. Consolidated Financial Statements ..... 5
  - (1) Consolidated Balance Sheets ..... 5
  - (2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income ..... 7
    - Consolidated Statements of Income ..... 7
    - Consolidated Statements of Comprehensive Income ..... 8
  - (3) Consolidated Statements of Cash Flows ..... 9
  - (4) Notes of Quarterly Consolidated Financial Statements ..... 10
    - (Note regarding going concern assumption) ..... 10
    - (Note regarding substantial change in shareholders' equity) ..... 10
    - (Subsequent Event) ..... 10
- 3. Supplementary information ..... 12
  - (1) Consolidated Financial Indicators for 1<sup>st</sup> Quarter of FY2013 ..... 12
  - (2) State of New Product Development ..... 16

## 1. [Qualitative Information for 1st Quarter of FY 2013]

### (1) Explanation about results of operations

Consolidated operating results in the first quarter of the fiscal year ended March 31, 2014 (April 1, 2013 to June 30, 2013) were as follows.

(millions of yen)

	1 <sup>st</sup> quarter of FY 2012	1 <sup>st</sup> quarter of FY 2013	Increase/ Decrease	% change
Net Sales	104,388	103,922	(466)	(0.4)
Cost of sales	40,641	43,530	2,889	7.1
Cost of sales ratio	38.9%	41.9%		
Gross profit	63,747	60,392	(3,355)	(5.3)
SG&A expenses	44,913	44,152	(761)	(1.7)
Operating Income	18,834	16,240	(2,594)	(13.8)
Non-operating income/loss	805	821	16	
Ordinary Income	19,639	17,061	(2,578)	(13.1)
Extraordinary income/loss	(831)	—	831	
Net Income	10,828	10,410	(418)	(3.9)

#### 【Net sales】

Net sales decreased 0.4%, or ¥0.4 billion, year-on-year, to ¥103.9 billion.

(millions of yen)

	1 <sup>st</sup> quarter of FY 2012	1 <sup>st</sup> quarter of FY 2013	Increase/ Decrease	% change
Pharmaceuticals	101,921	103,426	1,505	1.5
Domestic ethical drugs	90,517	88,543	(1,974)	(2.2)
Overseas ethical drugs	4,549	5,124	575	12.6
OTC products	1,356	1,139	(217)	(16.0)
Others in Pharmaceuticals	5,499	8,620	3,121	56.8
Others	2,467	496	(1,971)	(79.9)

In the pharmaceuticals segment, net sales were ¥103.4 billion, up 1.5%, or ¥1.5 billion, year-on-year.

- In the domestic sales of ethical drugs, continued favorable sales growth was recorded by Remicade, an anti-TNF  $\alpha$  monoclonal antibody. In addition, new drugs such as TETRABIK, a combined vaccine for four diseases, which was launched in October 2012, made contribution. However, there were the growing impact of generics and the cancellation of alliance in generics. As a result, the domestic sales of ethical drugs decreased 2.2%, year-on-year, to ¥88.5 billion.

- Overseas sales of ethical drugs increased 12.6%, year-on-year, to ¥5.1 billion, and sales of OTC products decreased 16.0%, year-on-year, to ¥1.1 billion.
- Sales of others in pharmaceuticals increased 56.8%, year-on-year, to ¥8.6 billion due to the increase in royalty revenue from Gilenya, for the treatment of multiple sclerosis, licensed to Novartis.

In others, sales decreased 79.9%, or ¥1.9 billion, year-on-year, due to the transfer of fine chemical operations in July 2012.

#### 【Operating income】

Operating income decreased 13.8%, or ¥2.5 billion, year-on-year, to ¥16.2 billion.

- Gross profit decreased ¥3.3 billion, year-on-year, to ¥60.3 billion because plasma fractionation products were changed from the own products to other company's products after the integration of the plasma fractionation operations.

The cost of sales ratio worsened by 3.0 percentage points, year-on-year.

- SG&A expenses decreased ¥0.7 billion, year-on-year, to ¥44.1 billion, due to the decrease in expenses related to the plasma fractionation operations caused by the above integration. R&D expenses were ¥17.5 billion, accounting for 16.9% of net sales.

#### 【Ordinary income and net income】

Ordinary income was down 13.1%, or ¥2.5 billion, year-on-year, to ¥17.0 billion, and net income was down 3.9%, or ¥0.4 billion, year-on-year, to ¥10.4 billion.

- In the previous fiscal year, the Company recorded extraordinary losses, such as loss on valuation of investment in securities, on the other hand, the Company didn't record any extraordinary items in the period under review. Consequently, extraordinary income/loss improved by 0.8 billion, year-on-year.

#### 【Comprehensive income】

Net income before minority interests was ¥10.4 billion, due to other comprehensive income of ¥1.0 billion, and comprehensive income of ¥11.4 billion. Comprehensive income attributable to shareholders of the Company was ¥11.1 billion.

## (2) Explanation about financial position

### 【Balance sheets】

(millions of yen)

	End of FY 2012 (As of March 31, 2013)	End of 1 <sup>st</sup> quarter of FY 2013 (As of June 30, 2013)	Increase/ Decrease
Current assets	476,686	466,631	(10,055)
Fixed assets	390,088	387,055	(3,033)
Total assets	866,774	853,686	(13,088)
Liabilities	113,852	100,564	(13,288)
Net assets	752,922	753,122	200
Total liabilities and net assets	866,774	853,686	(13,088)

Total assets at the end of the first quarter were ¥853.6 billion, a decrease of ¥13.0 billion from the end of the previous fiscal year. Major factors causing changes in the balance sheet in comparison with the previous year-end were as follows.

- Marketable securities decreased. Consequently, total current assets were down ¥10.0 billion, to ¥466.6 billion.
- Intangible fixed assets decreased by the amortization of goodwill. Consequently, total fixed assets were down ¥3.0 billion from the previous fiscal year-end, to ¥387.0 billion.
- Income taxes payable decreased. Consequently, total liabilities were down ¥13.2 billion, to ¥100.5 billion.
- Total net assets were up by ¥0.2 billion, to ¥753.1 billion. Net income was ¥10.4 billion, and dividends paid totaled ¥11.2 billion. As a result, retained earnings decreased ¥0.8 billion, however, accumulated other comprehensive income increased. The equity ratio was 87.6%, compared with 86.3% a year earlier.

### 【Cash flows】

(millions of yen)

	1 <sup>st</sup> quarter of FY 2012	1 <sup>st</sup> quarter of FY 2013	Increase/ Decrease
Operating activities	11,504	(2,418)	(13,922)
Investing activities	(1,095)	9,812	10,907
Financing activities	(11,066)	(11,281)	(215)
Change in cash and cash equivalents	(233)	(3,201)	(2,968)
At beginning of year	54,344	58,745	4,401
At end of year	54,111	55,544	1,433

Net decrease in cash and cash equivalents was ¥3.2 billion, and the balance of cash and cash equivalents at the end of the period under review was ¥55.5 billion.

- Net cash used in operating activities was ¥2.4 billion. Cash outflows included income taxes paid of ¥15.9 billion and increase in notes and accounts receivable-trade of ¥5.4 billion, while cash inflows included income before income taxes and minority interests of ¥17.0 billion.
- Net cash provided by investing activities was ¥9.8 billion, due to redemption of marketable securities.
- Net cash used in financing activities was ¥11.2 billion, due in part to dividends paid.

### (3) Explanation about future prediction information of consolidated results forecasts

There are no revisions to the first half and full-year results forecasts for the fiscal year ending March 31, 2014, which were announced on May 8, 2013.

【Consolidated results forecasts for first half of the current fiscal year (released on May 8, 2013)】

(millions of yen)

	Results for first half of FY 2012	Forecasts for first half of FY 2013	Increase/Decrease	% change
Net sales	203,829	200,000	(3,829)	(1.9)
Operating income	32,246	30,000	(2,246)	(7.0)
Ordinary income	33,119	31,000	(2,119)	(6.4)
Net income	19,492	19,000	(492)	(2.5)

【Consolidated results forecasts for the current fiscal year (released on May 8, 2013)】

(millions of yen)

	Results for FY 2012	Forecasts for FY 2013	Increase/Decrease	% change
Net sales	419,179	417,000	(2,179)	(0.5)
Operating income	68,968	70,000	1,032	1.5
Ordinary income	69,392	71,500	2,108	3.0
Net income	41,892	44,000	2,108	5.0

### 3. Consolidated Financial Statements

#### (1) Consolidated Balance Sheets

(millions of yen)

Year Accounts	As of March 31, 2013	As of June 30, 2013
	Amount	Amount
<b>Assets</b>		
<b>Current assets</b>		
Cash and time deposits	20,281	18,631
Notes and accounts receivable, trade	129,868	135,412
Marketable securities	63,993	50,231
Merchandise and finished goods	67,944	67,056
Work in process	717	963
Raw materials and supplies	24,122	24,492
Deposits	151,554	151,692
Deferred income taxes	8,373	5,673
Other	9,877	12,524
Less allowance for doubtful receivables	(43)	(43)
<b>Total current assets</b>	<b>476,686</b>	<b>466,631</b>
<b>Fixed assets</b>		
<b>Property, plant and equipment</b>		
Buildings and structures, net	33,833	33,743
Machinery, equipment and vehicles, net	12,271	13,683
Tools, furniture and fixtures, net	4,835	4,886
Land	38,998	38,977
Leased equipment, net	59	54
Construction in progress	2,287	2,733
<b>Total property, plant and equipment</b>	<b>92,283</b>	<b>94,076</b>
<b>Intangible fixed assets</b>		
Goodwill	99,527	96,926
Other	4,632	4,960
<b>Total intangible fixed assets</b>	<b>104,159</b>	<b>101,886</b>
<b>Investments and other assets</b>		
Investment in securities	120,984	120,359
Deferred income taxes	4,173	4,033
Prepaid pension expenses	36,883	36,257
Other	31,608	30,446
Less allowance for doubtful receivables	(2)	(2)
<b>Total investments and other assets</b>	<b>193,646</b>	<b>191,093</b>
<b>Total fixed assets</b>	<b>390,088</b>	<b>387,055</b>
<b>Total assets</b>	<b>866,774</b>	<b>853,686</b>



(millions of yen)

Year Accounts	As of	As of
	March 31, 2013	June 30, 2013
	Amount	Amount
<b>Liabilities</b>		
<b>Current liabilities</b>		
Notes and accounts payable, trade	38,072	37,610
Short-term debt	1,174	1,218
Accounts payable, other	15,589	15,582
Income taxes payable	16,191	3,335
Reserve for employees' bonuses	10,291	5,436
Other reserve	148	128
Other	4,653	9,916
<b>Total current liabilities</b>	<b>86,118</b>	<b>73,225</b>
<b>Long-term liabilities</b>		
Deferred income taxes	8,365	8,446
Accrued retirement benefits for employees	9,443	9,196
Reserve for health management allowances for HIV compensation	1,627	1,627
Reserve for health management allowances for SMON compensation	3,172	3,079
Reserve for HCV litigation	3,593	3,439
Other	1,534	1,552
<b>Total long-term liabilities</b>	<b>27,734</b>	<b>27,339</b>
<b>Total liabilities</b>	<b>113,852</b>	<b>100,564</b>
<b>Net assets</b>		
<b>Shareholders' equity</b>		
Common stock	50,000	50,000
Capital surplus	451,186	451,186
Retained earnings	243,621	242,812
Treasury stock, at cost	(487)	(488)
<b>Total shareholders' equity</b>	<b>744,320</b>	<b>743,510</b>
<b>Accumulated other comprehensive income</b>		
Unrealized holding gains (losses) on securities	7,189	7,004
Deferred (losses) gains on hedges	1,640	1,551
Translation adjustments	(5,220)	(4,169)
<b>Total accumulated other comprehensive income</b>	<b>3,609</b>	<b>4,386</b>
<b>Minority interests</b>	<b>4,993</b>	<b>5,226</b>
<b>Total net assets</b>	<b>752,922</b>	<b>753,122</b>
<b>Total liabilities and net assets</b>	<b>866,774</b>	<b>853,686</b>

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income  
(Consolidated Statements of Income)

(millions of yen)

Year Accounts	April 01, 2012– June 30, 2012	April 01, 2013– June 30, 2013
	Amount	Amount
<b>Net sales</b>	<b>104,388</b>	<b>103,922</b>
Cost of sales	40,641	43,530
Gross profit	63,747	60,392
Selling, general and administrative expenses		
Advertising expenses	826	809
Sales promotion expenses	1,945	1,986
Salaries and allowances	6,689	6,423
Provision for bonuses	3,021	2,935
Retirement benefit expenses	1,393	758
Depreciation and amortization	311	332
Research and development expenses	16,923	17,553
Amortization of goodwill	2,531	2,601
Other	11,274	10,755
Total selling, general and administrative expenses	44,913	44,152
<b>Operating income</b>	<b>18,834</b>	<b>16,240</b>
Non-operating income		
Interest income	410	361
Dividend income	411	446
Equity in earning of affiliates	392	353
Foreign exchange income	—	576
Other	465	272
Total non-operating income	1,678	2,008
Non-operating expenses		
Interest expense	11	18
Donations	246	222
Taxes and dues	257	196
Foreign exchange loss	85	—
Other	274	751
Total non-operating expenses	873	1,187
<b>Ordinary income</b>	<b>19,639</b>	<b>17,061</b>
Extraordinary gain		
Gain on sales of investment in securities	201	—
Total extraordinary income	201	—
Extraordinary loss		
Loss on valuation of investment in securities	745	—
Loss on impairment of fixed assets	184	—
Loss on business integration	103	—
Total extraordinary losses	1,032	—
<b>Income before income taxes and minority interests</b>	<b>18,808</b>	<b>17,061</b>
Income taxes—current	5,699	3,414
Income taxes—deferred	2,193	3,211
Total income taxes	7,892	6,625
Net income before minority interests	10,916	10,436
Minority interests	88	26
<b>Net income</b>	<b>10,828</b>	<b>10,410</b>

(Consolidated Statements of Comprehensive Income)

(Millions of yen)

Year Accounts	April 01, 2012– June 30, 2012	April 01, 2013– June 30, 2013
	Amount	Amount
<b>Net income before minority interests</b>	<b>10,916</b>	<b>10,436</b>
Other comprehensive income (loss)		
Unrealized holding gains (losses) on securities	171	(185)
Deferred (losses) gains on hedges	(354)	(90)
Translation adjustments	1,360	1,278
Other comprehensive income (loss) of equity method companies attributable to the Company	15	12
Total other comprehensive income (loss)	1,192	1,015
<b>Comprehensive income</b>	<b>12,108</b>	<b>11,451</b>
Comprehensive income (loss) attributable to:		
Shareholders of the Company	11,772	11,187
Minority interests	336	264

(3) Consolidated Statements of Cash Flows

(millions of yen)

Year Accounts	April 01, 2012– June 30, 2012	April 01, 2013– June 30, 2013
<b>Cash flows from operating activities:</b>		
Income before income taxes and minority interests	18,808	17,061
Depreciation and amortization	2,150	2,084
Loss on impairment of fixed assets	184	–
Amortization of goodwill	2,531	2,601
Increase (decrease) in accrued retirement benefits for employees	(289)	(263)
Decrease (increase) in prepaid pension expenses	876	626
Increase (decrease) in reserve for HCV litigation	(293)	(154)
Interest and dividend income	(821)	(807)
Loss (gain) on sale of investment in securities	(201)	–
Loss (gain) on valuation of investment in securities	745	–
Equity in (earnings) losses of affiliates	(392)	(353)
Loss on business integration	103	–
Decrease (increase) in notes and accounts receivable, trade	(7,090)	(5,481)
Decrease (increase) in inventories	(5,955)	367
Increase (decrease) in notes and accounts payable, trade	9,959	(300)
Increase (decrease) in accounts payable, other	(838)	(1,248)
Other, net	(1,874)	(1,338)
Subtotal	17,603	12,795
Interest and dividends received	868	721
Interest paid	(11)	(24)
Income taxes paid	(6,956)	(15,910)
<b>Net cash provided by (used in) operating activities</b>	<b>11,504</b>	<b>(2,418)</b>
<b>Cash flows from investing activities:</b>		
Purchase of marketable securities	(16,500)	(11,500)
Proceeds from sales and redemption of marketable securities	16,000	24,250
Increase in time deposits	(44)	(1,126)
Decrease in time deposits	479	631
Purchase of property, plant and equipment	(1,852)	(2,500)
Purchase of intangible fixed assets	(316)	(266)
Purchase of investment in securities	(39)	(970)
Proceeds from sales and redemption of investment in securities	1,351	1,511
Other, net	(174)	(218)
<b>Net cash provided by (used in) investing activities</b>	<b>(1,095)</b>	<b>9,812</b>
<b>Cash flows from financing activities:</b>		
Increase (decrease) in short-term debt, net	165	(25)
Cash dividends paid	(11,219)	(11,219)
Other, net	(12)	(37)
<b>Net cash provided by (used in) financing activities</b>	<b>(11,066)</b>	<b>(11,281)</b>
<b>Effect of exchange rate change on cash and cash equivalents</b>	<b>424</b>	<b>686</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(233)</b>	<b>(3,201)</b>
<b>Cash and cash equivalents at beginning of the year</b>	<b>54,344</b>	<b>58,745</b>
<b>Cash and cash equivalents at end of the period</b>	<b>54,111</b>	<b>55,544</b>

#### **(4) Notes of Quarterly Consolidated Financial Statements**

##### **(Note regarding going concern assumption)**

Not applicable.

##### **(Note regarding substantial change in shareholders' equity)**

Not applicable.

##### **(Subsequent Event)**

###### Acquisition of Shares

The Company resolved that the Company will acquire, together with Philip Morris Investments B.V. which is a subsidiary of Philip Morris International Inc., all of the shares of Medicago Inc. at the board meeting held on July 12, 2013, and the Company reached an agreement with Medicago.

After the acquisition, Medicago will be jointly owned by the Company and Philip Morris Investments (shareholding ratio 60:40, respectively).

###### 1. Purpose for Acquisition of Shares

Under the Medium-Term Management Plan 11-15—New Value Creation—which ends in March 2016, the Company is working to create new pharmaceuticals that address unmet medical needs and build a global management foundation. Under the plan, the Company aims to make progress in the field of vaccines through the acquisition of new biologics technologies. Vaccines are a field in which growth is anticipated on a global basis and are one of the fields in which the Company is striving to implement development in global markets.

Medicago is a biological pharmaceutical company with special strengths in R&D for new vaccines using Virus Like Particle (VLP) technology. Medicago has proprietary technologies for the production of VLPs inside plant cells using genetic engineering and the efficient extraction and purification of those VLPs. Also, VLPs have the same external structure as viruses without the core genetic material, so VLP vaccines are expected to offer a high level of immunization effectiveness. In addition, with no virus replication in the body, these vaccines also offer superior safety. Accordingly, this promising vaccine technology is drawing widespread attention.

In September 2011, the Company acquired 6% of Medicago's shares and in February 2012, concluded a research collaboration agreement with Medicago regarding new vaccines using technologies for the production of plant-derived VLPs. The two companies have conducted joint research, such as in the rotavirus VLP vaccine field.

Through its research collaboration with Medicago, the Company evaluated Medicago's VLP technology. Consequently, the Company decided that this technology was highly useful, that it could be employed to manufacture efficiently a wide variety of vaccines, and that the acquisition of Medicago would enable the Company to further strengthen its pipeline.

The company will work in the R&D of a wide variety of vaccines based on Medicago's VLP technology and contribute to human healthcare.

## **2. Overview of other party in share acquisition**

The Company will acquire all of Medicago's shares (excluding shares which the Company and Philip Morris Investments already owned) by paying cash to the existing shareholders.

## **3. Name, business activities, and scale of the acquired company**

(1) Name

Medicago Inc.

(2) Business activities

R&D in VLP vaccines using a transient expression system in plants

(3) Capital (Note)

CAD 117 million

(4) Consolidated net sales (Note)

CAD 5 million

(Note) These numbers were announced in the financial results for year ended December 31, 2012

## **4. Timing of share acquisition**

September 2013 (planned)

## **5. Number of shares to be acquired, acquisition price and percentage of ownership after transfer**

(1) Number of shares to be acquired

147,666,241 shares (Note)

(2) Acquisition price

CAD179million (Note)

(3) Shareholding ratio after transfer

60.0%

(Note) These numbers might increase if its stock options and warrants are executed . Shareholding ratio after transfer will remain the same even if stock options and warrants are executed.

## **6. Fund procurement and method of payment**

Own fund

### 3. Supplementary information

#### (1) Consolidates Financial Indications for 1st Quarter of FY2013

##### i. PL

[Billion yen]

	Q1/FY2013		Q1/FY2012		Year-on-year		Comparison to forecasts		Notes [year-on-year comparison]
	Actual	Ratio to sales %	Actual	Ratio to sales %	Increase (decrease)	Change %	Forecasts for 1st half of FY2013*1	Achieved %	
Net sales	103.9	100.0 %	104.4	100.0 %	(0.5)	(0.4)	200.0	52.0	Foreign sales ratio Q1 FY2012: 8.4% Q1 FY2013: 12.0% Average exchange rate Q1 FY2012: 1US \$ = ¥ 79.75 Q1 FY2013: 1US \$ = ¥ 99.23
Domestic	91.4	88.0	95.6	91.6	(4.2)	(4.4)	175.9	52.0	
Overseas	12.5	12.0	8.8	8.4	3.7	42.2	24.1	51.9	
Pharmaceuticals	103.4	99.5	101.9	97.6	1.5	1.5	199.3	51.9	Ethical drugs domestic sales (2.0) Ethical drugs overseas sales +0.6 Contracted manufacturing products (0.2) Licensing fee, etc. +3.3 See page 13, Sales of Main Products
Domestic	91.3	87.8	93.7	89.8	(2.4)	(2.6)	175.7	52.0	
Overseas	12.1	11.7	8.2	7.9	3.9	47.6	23.6	51.4	
Others	0.5	0.5	2.5	2.4	(2.0)	(79.9)	0.7	70.9	
Domestic	0.1	0.1	1.9	1.8	(1.8)	(93.2)	0.2	65.0	
Overseas	0.4	0.4	0.6	0.5	(0.2)	(35.6)	0.5	73.2	
Cost of sales	43.5	41.9	40.6	38.9	2.9	7.1	78.0	55.8	
Gross operation profit	60.4	58.1	63.7	61.1	(3.4)	(5.3)	122.0	49.5	
SG&A expenses	44.2	42.5	44.9	43.0	(0.8)	(1.7)	92.0	48.0	
R&D expenses	17.6	16.9	16.9	16.2	0.6	3.7	35.4	49.6	
Non-R&D expenses	26.6	25.6	28.0	26.8	(1.4)	(5.0)	56.6	47.0	
Labor cost	11.9	11.4	12.9	12.4	(1.1)	(8.2)	23.8	49.8	
Amortization of goodwill*2	2.6	2.5	2.5	2.4	0.1	2.8	5.2	50.0	
Others	12.1	11.7	12.5	12.0	(0.4)	(3.2)	27.6	44.0	
Operating income	16.2	15.6	18.8	18.0	(2.6)	(13.8)	30.0	54.1	
Non-operating income	2.0		1.7		0.3				
Interest income	0.4		0.4		0.0				
Dividend income	0.4		0.4		0.0				
Equity in earnings of income	0.4		0.4		0.0				
Foreign exchange gain	0.6		-		0.6				
Others	0.3		0.5		(0.2)				
Non-operating expenses	1.2		0.9		0.3				
Tax and dues	0.2		0.3		(0.1)				
Donations	0.2		0.2		0.0				
Foreign exchange losses	-		0.1		(0.1)				
Others	0.8		0.3		0.5				
Ordinary income	17.1	16.4	19.6	18.8	(2.6)	(13.1)	31.0	55.0	
Extraordinarily income	-		0.2		(0.2)				
Gains on sale of investments in securities	-		0.2		(0.2)				
Extraordinary losses	-		1.0		(1.0)				
Loss on valuation of investment in securities	-		0.7		(0.7)				
Loss on impairment of fixed assets	-		0.2		(0.2)				
Loss on business integration	-		0.1		(0.1)				
Net income	10.4	10.0	10.8	10.4	(0.4)	(3.9)	19.0	54.8	
Total labor cost	20.9	20.2	22.5	21.6	(1.6)	(7.0)	41.6	50.4	

\*1: Published forecasts announced on May 8, 2013 in the financial results for FY2012.

\*2: Clear off 150.5 billion yen within 15 years

ii. Sales of Main Products

[Billion yen]

	Q1/FY2013	Year-on-year			Comparison to forecasts	
		Q1/FY2012	Increase (decrease)	Change %	Forecasts for 1st half of FY2013*1	Achieved %
<b>Ethical drugs</b>	<b>102.3</b>	100.6	1.7	1.7	196.6	52.0
Ethical drugs domestic sales	<b>88.5</b>	90.5	(2.0)	(2.2)	169.7	52.2
Remicade	<b>19.2</b>	17.9	1.3	7.1	38.6	49.7
Ceredist	<b>4.7</b>	5.0	(0.3)	(5.8)	9.0	52.4
Maintate	<b>4.0</b>	3.6	0.3	9.2	7.5	52.9
Talion	<b>2.7</b>	3.1	(0.3)	(10.5)	5.4	50.6
Kremezin	<b>3.2</b>	3.1	0.1	3.4	6.3	51.4
Urso	<b>3.3</b>	3.5	(0.2)	(5.8)	5.9	55.7
Venoglobulin IH	<b>2.9</b>	2.9	0.0	1.3	5.7	51.0
Anplag	<b>3.1</b>	3.7	(0.6)	(15.6)	5.9	52.4
Radicut	<b>3.0</b>	3.7	(0.7)	(20.0)	5.0	59.4
Depas	<b>2.6</b>	2.8	(0.2)	(7.3)	4.7	54.5
Simponi	<b>2.1</b>	1.0	1.0	98.3	4.1	50.4
Lexapro	<b>1.0</b>	0.8	0.3	37.2	3.3	31.2
Herbesser	<b>1.9</b>	2.1	(0.3)	(12.2)	3.6	51.4
Tanatril	<b>1.7</b>	2.0	(0.3)	(14.1)	3.3	51.3
BIKEN products [vaccines]	<b>8.8</b>	6.1	2.7	43.7	12.7	69.2
Tetrabik	<b>2.9</b>	-	2.9	-	4.3	67.3
Influenza	<b>(0.1)</b>	0.0	0.0	-	1.4	-
Tanabe Seiyaku Hanbai Products *2	<b>3.5</b>	4.8	(1.3)	(27.5)	6.7	52.4
Ethical drugs overseas sales	<b>5.1</b>	4.5	0.6	12.6	10.9	47.0
Herbesser	<b>1.5</b>	1.1	0.3	27.5	2.4	60.8
Argatroban (Novastan)	<b>0.7</b>	0.7	(0.1)	(8.0)	0.9	73.0
Tanatril	<b>0.5</b>	0.5	0.0	3.8	0.9	51.9
Contracted manufacturing products *3	<b>1.5</b>	1.7	(0.2)	(12.2)	3.0	50.4
Licensing fee, etc.	<b>7.1</b>	3.8	3.3	88.2	13.0	54.7
Royalty from Gilenya	<b>6.5</b>	2.7	3.7	137.1	-	-
<b>OTC products</b>	<b>1.1</b>	1.4	(0.2)	(16.0)	2.7	42.2
<b>Total pharmaceuticals</b>	<b>103.4</b>	101.9	1.5	1.5	199.3	51.9

\*1: Published forecasts announced on May 8, 2013 in the financial results for FY2012.

\*2: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

\*3: Active pharmaceutical ingredients and others ordered by other companies.



iii Quaterly Trend (PL)

[Billion yen]

	FY2012					FY2013		
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2012 Actual	Q1 Apr. to Jun.	Forecasts for 1st Half of FY2013	Forecasts for FY2013
Net sales	104.4	99.4	118.7	96.6	419.2	103.9	200.0	417.0
	24.9%	23.7%	28.3%	23.0%	100.0%	24.9%	48.0%	100.0%
Domestic	95.6	89.8	105.2	80.8	371.4	91.4	175.9	366.1
	25.7%	24.2%	28.3%	21.8%	100.0%	25.0%	48.0%	100.0%
Overseas	8.8	9.6	13.5	15.8	47.7	12.5	24.1	50.9
	18.4%	20.2%	28.3%	33.1%	100.0%	24.6%	47.3%	100.0%
Pharmaceuticals	101.9	98.8	118.2	95.8	414.7	103.4	199.3	415.7
	24.6%	23.8%	28.5%	23.1%	100.0%	24.9%	47.9%	100.0%
Domestic	93.7	89.7	105.1	80.7	369.1	91.3	175.7	365.6
	25.4%	24.3%	28.5%	21.9%	100.0%	25.0%	48.1%	100.0%
Overseas	8.2	9.2	13.1	15.1	45.6	12.1	23.6	50.1
	18.0%	20.1%	28.8%	33.1%	100.0%	24.2%	47.1%	100.0%
Others	2.5	0.6	0.6	0.8	4.5	0.5	0.7	1.3
	54.9%	13.9%	12.5%	18.7%	100.0%	38.2%	53.8%	100.0%
Domestic	1.9	0.1	0.2	0.2	2.4	0.1	0.2	0.5
	80.4%	5.8%	7.3%	6.6%	100.0%	26.0%	40.0%	100.0%
Overseas	0.6	0.5	0.4	0.7	2.1	0.4	0.5	0.8
	26.7%	23.0%	18.2%	32.2%	100.0%	45.8%	62.5%	100.0%
Cost of sales	40.6	38.6	47.5	39.7	166.4	43.5	78.0	163.0
Sales Cost Ratio	38.9%	38.8%	40.0%	41.0%	39.7%	41.9%	39.0%	39.1%
Gross operating profit	63.7	60.8	71.3	57.0	252.8	60.4	122.0	254.0
	25.2%	24.1%	28.2%	22.5%	100.0%	23.8%	48.0%	100.0%
SG&A expenses	44.9	47.4	44.7	46.8	183.8	44.2	92.0	184.0
	24.4%	25.8%	24.3%	25.5%	100.0%	24.0%	50.0%	100.0%
R&D expenses	16.9	17.3	17.0	15.3	66.5	17.6	35.4	70.5
	25.4%	26.0%	25.5%	23.0%	100.0%	24.9%	50.2%	100.0%
Non-R&D expenses	28.0	30.1	27.7	31.5	117.3	26.6	56.6	113.5
	23.9%	25.7%	23.6%	26.9%	100.0%	23.4%	49.9%	100.0%
Labor costs	12.9	13.0	12.5	13.5	51.9	11.9	23.8	47.9
	24.9%	25.1%	24.0%	25.9%	100.0%	24.8%	49.7%	100.0%
Amortization of goodwill	2.5	2.5	2.6	2.6	10.3	2.6	5.2	10.4
	24.6%	24.6%	25.5%	25.3%	100.0%	25.0%	50.0%	100.0%
Others	12.5	14.5	12.6	15.5	55.1	12.1	27.6	55.2
	22.8%	26.3%	22.8%	28.1%	100.0%	22.0%	50.0%	100.0%
Operating income	18.8	13.4	26.6	10.1	69.0	16.2	30.0	70.0
	27.3%	19.4%	38.6%	14.7%	100.0%	23.2%	42.9%	100.0%
Ordinary income	19.6	13.5	27.0	9.3	69.4	17.1	31.0	71.5
	28.3%	19.4%	38.9%	13.3%	100.0%	23.9%	43.4%	100.0%
Net income	10.8	8.7	15.8	6.6	41.9	10.4	19.0	44.0
	25.8%	20.7%	37.6%	15.9%	100.0%	23.7%	43.2%	100.0%

The each figure (excluding Cost of sales) in the lower displays the progress rate.

## iv. Quaterly Trend (Sales of Main Products)

[Billion yen]

	FY2012					FY2013		
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2012 Actual	Q1 Apr. to Jun.	Forecasts for 1st Half of FY2013	Forecasts for FY2013
<b>Ethical drugs</b>	100.6 24.6%	97.4 23.8%	116.7 28.5%	94.8 23.1%	409.4 100.0%	102.3 24.9%	196.6 47.9%	410.5 100.0%
Ethical drugs domestic sales	90.5 25.4%	86.1 24.1%	102.0 28.6%	78.0 21.9%	356.6 100.0%	88.5 25.0%	169.7 47.9%	354.5 100.0%
Remicade	17.9 24.4%	18.8 25.6%	19.8 27.0%	17.0 23.1%	73.5 100.0%	19.2 24.4%	38.6 49.1%	78.6 100.0%
Ceredist	5.0 27.2%	4.5 24.6%	5.0 27.0%	3.9 21.3%	18.4 100.0%	4.7 25.9%	9.0 49.5%	18.2 100.0%
Maintate	3.6 25.8%	3.3 23.6%	4.0 28.1%	3.2 22.6%	14.1 100.0%	4.0 25.1%	7.5 47.5%	15.8 100.0%
Talion	3.1 21.3%	2.2 15.5%	3.7 25.8%	5.3 37.3%	14.3 100.0%	2.7 17.4%	5.4 34.4%	15.7 100.0%
Kremezin	3.1 25.7%	2.9 23.6%	3.5 28.7%	2.7 22.0%	12.2 100.0%	3.2 24.7%	6.3 48.1%	13.1 100.0%
Urso	3.5 26.3%	3.3 24.6%	3.7 27.6%	2.9 21.6%	13.3 100.0%	3.3 27.2%	5.9 48.8%	12.1 100.0%
Venoglobulin IH	2.9 26.1%	2.7 24.4%	3.2 29.2%	2.2 20.3%	11.0 100.0%	2.9 24.8%	5.7 48.7%	11.7 100.0%
Anplag	3.7 28.3%	3.1 24.3%	3.5 27.0%	2.7 20.5%	13.0 100.0%	3.1 26.6%	5.9 50.9%	11.6 100.0%
Radicut	3.7 28.0%	3.3 24.6%	3.7 27.7%	2.6 19.8%	13.3 100.0%	3.0 30.3%	5.0 51.0%	9.8 100.0%
Depas	2.8 26.7%	2.5 24.4%	2.8 27.4%	2.2 21.5%	10.4 100.0%	2.6 26.9%	4.7 49.5%	9.5 100.0%
Simponi	1.0 19.7%	1.2 22.5%	1.6 29.5%	1.5 28.3%	5.3 100.0%	2.1 22.5%	4.1 44.6%	9.2 100.0%
Lexapro	0.8 16.5%	0.9 20.0%	1.4 31.0%	1.5 32.5%	4.6 100.0%	1.0 12.4%	3.3 39.8%	8.3 100.0%
Herbesser	2.1 27.7%	1.8 23.7%	2.1 27.9%	1.6 20.8%	7.6 100.0%	1.9 26.4%	3.6 51.4%	7.0 100.0%
Tanatril	2.0 27.7%	1.7 24.3%	2.0 27.6%	1.5 20.5%	7.1 100.0%	1.7 26.9%	3.3 52.4%	6.3 100.0%
BIKEN products [vaccines]	6.1 21.3%	6.5 22.6%	11.4 39.5%	4.8 16.6%	28.8 100.0%	8.8 31.5%	12.7 45.5%	27.9 100.0%
Tetrabik	- -	- -	2.7 59.3%	1.8 40.7%	4.5 100.0%	2.9 32.2%	4.3 47.8%	9.0 100.0%
Influenza	0.0 (0.5%)	1.6 20.5%	6.8 88.7%	(0.7) (8.7%)	7.7 100.0%	(0.1) (0.7%)	1.4 17.3%	8.1 100.0%
Tanabe Seiyaku Hanbai products *1	4.8 25.5%	4.2 22.3%	5.5 29.2%	4.3 22.9%	19.0 100.0%	3.5 25.1%	6.7 47.9%	14.0 100.0%
Ethical drugs overseas sales *2	4.5 19.5%	5.6 24.0%	5.0 21.6%	8.2 35.0%	23.4 100.0%	5.1 24.3%	10.9 51.7%	21.1 100.0%
Herbesser	1.1 19.3%	1.2 19.4%	1.1 19.1%	2.5 42.2%	5.9 100.0%	1.5 29.8%	2.4 49.0%	4.9 100.0%
Argatroban (Novastan)	0.7 24.8%	0.7 23.5%	0.5 17.2%	1.0 34.6%	2.9 100.0%	0.7 36.5%	0.9 50.0%	1.8 100.0%
Tanatril	0.5 21.9%	0.4 20.2%	0.4 20.6%	0.8 37.3%	2.1 100.0%	0.5 27.5%	0.9 52.9%	1.7 100.0%
Contracted manufacturing products *3	1.7 25.3%	2.1 30.2%	1.3 18.8%	1.7 25.6%	6.8 100.0%	1.5 27.0%	3.0 53.6%	5.6 100.0%
Licensing fee, etc.	3.8 16.7%	3.6 15.9%	8.4 37.2%	6.9 30.3%	22.7 100.0%	7.1 24.3%	13.0 44.4%	29.3 100.0%
<b>OTC products</b>	1.4 25.6%	1.5 27.5%	1.5 27.8%	1.0 19.1%	5.3 100.0%	1.1 21.9%	2.7 51.9%	5.2 100.0%
<b>Total pharmaceuticals</b>	101.9 24.6%	98.8 23.8%	118.2 28.5%	95.8 23.1%	414.7 100.0%	103.4 24.9%	199.3 47.9%	415.7 100.0%

The each figure in the lower displays the progress rate.

\*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

\*2: In 2012, the settling days of overseas subsidiaries are changed from end of December to end of March, thus their accounting periods are for fifteen month from January, 2012 to March, 2013.

\*3: Active pharmaceutical ingredients and others ordered by other companies.

(2) State of New Product Development (As of July 31, 2013)

i. Pipeline in Japan

New Molecular Entities

Development code (Generic name)	Category (Indications)	Stage	Origin	Notes
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	NDA filed (May 2013)	In-house	
MP-214 (Cariprazine)	D3/D2 receptor partial agonist (Schizophrenia)	Phase 2b/3	Hungary: Gedeon Richter	
MT-4666	α7nACh receptor agonist (Dementia of Alzheimer's type)	Phase 2	US: EnVivo	
MT-3995	Selective mineralocorticoid receptor antagonist (Hypertention)	Phase 1	In-house	
MT-1303	S1P receptor functional antagonist (Multiple sclerosis)	Phase 1	In-house	

Additional Indications

Product name (Generic name)	Category (Indications)	Stage	Origin	Notes
Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus, additional combination)	sNDA filed (Feb. 2013)	In-house	
Radicut (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis*)	Phase 3	In-house	
Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Pediatric allergic rhinitis)	Phase 3	Japan: Ube Industries	
	(Pediatric atopic dermatitis)	Phase 3		
Telavic (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [genotype2] )	Phase 3	US:Vertex	
	(Chronic hepatitis C, [combination with Pegasys] )	Phase 3		
	(Chronic hepatitis C, [combination with Feron] )	Phase 3		
Remicade (Infliximab [recombinant])	Anti-human TNFα monoclonal antibody (Refractory Kawasaki disease*)	Phase 3	US:Janssen Biotech	
	(Behcet's disease with special lesions*)	Phase 3		
	(Pediatric Crohn's disease)	Phase 3		
	(Psoriasis: increased dose)	Phase 3		
Imusera (Fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Phase 3	In-house	Co-developed with Novartis Pharma, Multinational study
Cholebine (Colestimide[JAN])	Bile acid signal regulation (Type 2 diabetes mellitus)	Phase 2	In-house	
	Non-absorbed phosphate binder (Hyperphosphatemia)	Phase 1		

\* Orphan drug designated

## ii. Pipeline Overseas

### New Molecular Entities

Development code (Generic name)	Category (Indications)	Region	Stage	Origin
MP-424 (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C)	Taiwan	Filed (Jan. 2013)	US:Vertex
		Korea	Phase 1	
MP-146	Uremic toxin adsorbent (Chronic kidney disease)	US, Europe	Phase 3	Japan:Kureha
MT-9938 (Nalfurafine)	$\kappa$ -opioid receptor agonist (Refractory pruritus in hemodialysis)	US, Canada	Phase 2	Japan:Toray
MP-513 (Teneligiptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Europe	Phase 2	In-house
		US	Phase 1	
MT-3995	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe	Phase 2	In-house
MT-1303	S1P receptor functional antagonist (Multiple sclerosis)	Europe	Phase 2	In-house
GB-1057 (Recombinant human serum albumin)	Recombinant human serum albumin (Stabilizing agent)	US	Phase 1	In-house
MP-124	PARP inhibitor (Acute ischemic stroke)	US, Canada	Phase 1	In-house
MP-157	Angiotensin Type 2 receptor agonist (Hypertention)	Europe	Phase 1	In-house

### Additional Indications

Development code/Product name (Generic name)	Category (Indications)	Region	Stage	Origin
MCI-196/BindRen Colestilan[INN]	Non-absorbed phosphate binder (Pediatric hyperphosphatemia)	Europe	Phase 3	In-house

### iii. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee (Notes)
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus)	Europe	MAA filed (Jul. 2012 <sup>*1</sup> )	US: Janssen Pharmaceuticals
	(Type2 diabetes mellitus / fixed dose combination with metformin, IR <sup>2</sup> )	US	NDA filed (Feb. 2013 <sup>*1</sup> )	
	(Type2 diabetes mellitus / fixed dose combination with metformin, IR <sup>2</sup> )	Europe	MAA filed (Mar. 2013)	
	(Obesity)	US, Europe	Phase 2	
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Korea	Phase 3	Korea: Handok Pharmaceuticals
FTY720 (Fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Multinational study	Phase 3	Switzerland: Novartis (Co-developed with Novartis Pharma in Japan)
T-0047 (Firategrast)	Cell adhesion inhibitor [ $\alpha$ 4 $\beta$ 7/ $\alpha$ 4 $\beta$ 1 inhibitor] (Multiple sclerosis)	Europe	Phase 2	UK: GlaxoSmithKline
MKC-242	5-HT1A receptor agonist (Insomnia)	US	Phase 2	US: MediciNova
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	France: Cyrenaic
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase 2	Japan: Maruho
MCC-847	Leukotriene D4 receptor antagonist (Asthma)	Korea	Phase 2	Korea: SAMA Pharma
sTU-199 (Tenatoprazole)	Proton pump inhibitor (Gastroesophageal reflux disease)	Europe	Phase 1	France: Negma/Sidem
TT-138	$\beta$ 3 receptor agonist (Pollakiuria, urinary incontinence)	US	Phase 1	US: MediciNova
MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism)	Japan	Phase 1	Japan: Kyowa Hakko Kirin
Wf-516	SSRI / 5HT1A receptor antagonists (Depression)	Europe	Phase 1	US: SONKEI Pharmaceuticals
Y-803	Bromodomain inhibitor (Hematological cancer)	US, Europe	Phase 1	Switzerland: OncoEthix (Development code: OTX015)

\*1 Revised to the month when the application was accepted

\*2 Immediate release

iv. Changes Since Previous Announcement on May 8, 2013

In-house Development

Development code/Product name (Generic name)	Category (Indications)	Region	As of May 8, 2013	As of July 31, 2013
Maintate (Bisoprolol)	Selective $\beta$ 1 blocker (Atrial fibrillation (tachycardiac))	Japan	sNDA filed (Sep. 2012)	Approved (Jun. 2013)
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Japan	Phase 3	NDA filed (May 2013)
MCI-196/BindRen Colestilan[INN]	Non-absorbed phosphate binder (Pediatric hyperphosphatemia)	Europe	None	Phase 3

Licensing-out

Development code (Generic name)	Category (Indications)	Region	As of May 8, 2013	As of July 31, 2013
TA-1790 (Avanafil)	PDE5 inhibitor (Erectile dysfunction)	Europe	MAA filed (Mar. 2012)	Approved (Jun. 2013)